NRC Health (NRC) exhibits 45.0% gross margins and 21.0% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 18.6x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 16.4% operating margin and 21.0% ROIC, outpacing sector cost of capital.
ROIC: 21.0% // GM: 45.0%YoY revenue trajectory of -4.0% paired with 3.03% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -4.0% // FCF YLD: 3.03%Altman Z-Score of 3.82 and Piotroski F-Score of 4/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.82 // F-SCORE: 4/9Trading at 44.8x trailing P/E (41.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 44.8x // EV/EBITDA: 18.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $23.49 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend 8.4% net margins.
NET MARGIN: 8.4% // D/E: 5.36x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NRC & activate live FRED threshold breach alerts.